Heart Failure

December 28, 2022

With less than a week to go until the close of 2022, our editorial team is celebrating the final week of the year by recapping some of our most popular stories and content from the past year. Here, we are highlighting our most popular episodes of the Don’t Miss a Beat Podcast from 2022.

December 20, 2022

A single-center, retrospective analysis provides new insight into the role of social isolation and social frailty in the risk of negative outcomes among those hospitalized with heart failure.

December 10, 2022

An analysis of data from the PARADIGM-HF trial provides insight into the utility of NYHA class for identifying risk among patients with mild forms of heart failure.

December 08, 2022

Published on December 8, the AHA's scientific statement aims to combat medical misinformation by offering clinicians an overview of the contemporary knowledge base surrounding complementary and alternative medicine in patients with heart failure.

November 26, 2022

The November 2022 cardiology month in review features the top content from AHA Scientific Sessions 2022, new data related to use of direct oral anticoagulation, and an FDA warning to companies over violations of the FD&C Act.

November 09, 2022

Viet Le, PA-C, discusses a study from Intermountain Healthcare examining clinical predictors of medical therapy-induced LVEF improvement in patients with heart failure with reduced ejection fraction in real-world settings.

November 07, 2022

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.

November 07, 2022

Results of the STRONG-HF trial provide the first evidence from a randomized clinical trial that rapid, in-hospital initiation of guideline-directed medical therapy in heart failure can improve patient outcomes.

November 06, 2022

Over a six-month period, SGLT2 inhibition with empagliflozin did not change left ventricular structure or function compared with placebo in people without diabetes or significant heart failure.

November 05, 2022

Presented at AHA 22, results of the IRONMAN trial indicate use of intravenous iron was associated with improved outcomes among people with heart failure with reduced ejection fraction and iron deficiency.